Cogent Biosciences
COGT

$9.52

3.9%

Market Cap: 1.04B

About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Employees: 164

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 13 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 4 (+2) [Q1 2024]

93% more call options, than puts

Call options by funds: $1.3M | Put options by funds: $677K

63% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 38

37% more capital invested

Capital invested by funds: $538M [Q4 2023] → $734M (+$197M) [Q1 2024]

2% more funds holding

Funds holding: 144 [Q4 2023] → 147 (+3) [Q1 2024]

10% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 31

1.06% less ownership

Funds ownership: 106.2% [Q4 2023] → 105.14% (-1.06%) [Q1 2024]

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$8

16%

downside

Avg. target

$15.15

59%

upside

High target

$20

110%

upside

13 analyst ratings

10 positive

77%

3 neutral

23%

0 negative

0%

Needham Ami Fadia	89%upside $18	Buy Reiterated	27 Jun 2024
HC Wainwright & Co. Robert Burns	100%upside $19	Buy Reiterated	17 Jun 2024
Needham Ami Fadia	89%upside $18	Buy Reiterated	17 Jun 2024
Wedbush David Nierengarten	5%upside $10	Neutral Reiterated	24 May 2024
HC Wainwright & Co. Robert Burns	100%upside $19	Buy Reiterated	13 May 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting

Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated lead-in data from the company's ongoing Phase 3 PEAK trial evaluating the selective and potent KIT mutant inhibitor, bezuclastinib, in combination with sunitinib, in patients with Gastrointestinal Stromal Tumors (GIST). The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1. Cogent also announced today a new Phase 2 clinical trial of bezuclastinib plus sunitinib in later line GIST patients, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC) and in collaboration with The Life Raft Group and Dana-Farber Cancer Institute.

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

Cogent Biosciences Reports First Quarter 2024 Financial Results

SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025

Cogent Biosciences Reports First Quarter 2024 Financial Results

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

NEW YORK , April 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cogent Biosciences, Inc. (NASDAQ: COGT) on behalf of the company's shareholders. The investigation seeks to determine whether Cogent Biosciences, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected by YE 2025

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on:

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

See News Rankings